Eleventh U.S. CRISPR-Cas9 Patent Awarded to University of California, U. Vienna, Charpentier

Genetic Engineering & Biotechnology News reports, “An 11th U.S. patent covering CRISPR-Cas9 claims has been granted to the Regents of the University of California (UC), the University of Vienna, and CRISPR pioneer Emmanuelle Charpentier, PhD, director and scientific member at the Max Planck Institute of Infection Biology, Berlin. U.S. Patent No. 10,385,360 “Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription,” was awarded on Tuesday by the U.S. Patent and Trademark Office (USPTO).”

Referencing client The University of California, Berkeley, Director Eldora L. Ellison, Ph.D. is quoted in the coverage saying “The USPTO has continually acknowledged the Doudna-Charpentier team’s groundbreaking work” and “True to UC’s mission as a leading public university, the patent granted today and others in its CRISPR-Cas9 portfolio will be applied for the betterment of society.”